Available
Delivered in France : 0.01€
(for every order > 35€)

Pages: 208
ISBN : 9782742007134
ISBN élec : 978-2-7420-1217-6
Printed in: English
Publication date: 14/10/2008

More than 12 million people with epilepsy have seizures that cannot be controlled by antiepileptic drugs. The term “drug-resistance” is abundantly used in the epilepsy literature but the definitions proposed differ considerably. It is used indifferently in a number of different settings: as a criterion for selection of patients eligible for new antiepileptic drug trials, for the selection of surgical candidates, for the design of epidemiological studies, for the design of studies on quality of life, for the definition of the epileptic encephalopathies (in comparison to more benign epilepsy syndromes), to mention but a few.
As a result, available studies are usually not comparable and referral to epilepsy specialists is unacceptably delayed.
The present volume of Progress in Epileptic Disorders includes several focused chapters on all issues relating to drug-resistance and offers the basis for a consensus on a clinically meaningful core definition.
CONTENTS
Towards a clinically meaningful consensus on the definition of drug-resistance in focal epilepsies.
Epileptic encephalopathies versus "garden variety" focal epilepsies: can they be considered together?
The risk, correlates and temporal patterns of intractable epilepsy.
Are drug-resistant and drug-sensitive patients the same? Observations from the Glasgow database.
Refractory versus non-refractory status epilepticus: frequency, differentiating clinical features, and outcome.
Current knowledge on basic mechanisms of drug-resistance.
What should the characteristics be of a pertinent model to identify new treatments for drug resistant epilepsy?
Pertinent approaches for a genetic identification of resistance to
antiepileptic drugs.
Molecular targets of antiepileptic drugs
Antiepileptic drugs in development
with a real potential.
How many patients with drug-resistant epilepsy become seizure-free
because of surgery?
Neurostimulation for epilepsy
myth or reality ?
Beyond seizure reduction.
Early identification of
drug-resistant patients.
Prevention of drug resistance.